Lantheus Holdings Inc. (LNTH) Stock Price Down 6.7%
Lantheus Holdings Inc. (NASDAQ:LNTH) dropped 6.7% on Tuesday . The company traded as low as $6.80 and last traded at $7.07, with a volume of 226,365 shares trading hands. The stock had previously closed at $7.58.
LNTH has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Lantheus Holdings from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Friday, May 6th. Jefferies Group reaffirmed a “buy” rating on shares of Lantheus Holdings in a research note on Wednesday, May 4th. Finally, Credit Suisse Group AG set a $4.00 target price on shares of Lantheus Holdings and gave the company a “hold” rating in a research note on Friday, August 5th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $5.80.
The firm has a market cap of $216.36 million and a price-to-earnings ratio of 8.04. The company’s 50-day moving average price is $4.64 and its 200 day moving average price is $2.77.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, August 4th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.18. The firm earned $78 million during the quarter, compared to analysts’ expectations of $72.66 million. On average, equities analysts predict that Lantheus Holdings Inc. will post $0.48 EPS for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.